StockData

CytomX Therapeutics vs Janux Therapeutics

CTMX and JANX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CTMX and JANX compare

Janux Therapeutics is the larger company, worth 1.5 times as much as CytomX Therapeutics ($668M against $433M).

Janux Therapeutics grew revenue faster over the last twelve months (5367% versus −87.0% for CytomX Therapeutics).

Janux Therapeutics keeps more of each dollar of sales as profit, with a net margin of −427% compared with −435% at CytomX Therapeutics.

Janux Therapeutics scores higher on the StockData Score (12 against 8 for CytomX Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCTMXJANX
Size and price
Market cap$433M$668M
Share price$1.99$10.92
Change, 1 year−48.6%−60.2%
Change, 5 years−70.6%−38.2%
Beta (5Y)1.520.98
Employees69109
StockData Score
Total score812 (better)
Valuation score13 (better)
Growth score11
Performance score12 (better)
Health score56 (better)
Dividend score00
Valuation
P/S23.6× (better)27.8×
P/B1.4×0.7× (better)
FCF yield−19.1%−6.3% (better)
Fair value–$16.90
Margin of safety–35.4%
Growth
Revenue growth (TTM)−87.0%5367% (better)
Revenue growth, 5Y average2.2%–
Net income growth (TTM)−266%–
EPS growth (TTM)−179%–
Profitability
Operating margin−476% (better)−598%
Net margin−435%−427% (better)
FCF margin−451%−175% (better)
Return on equity−37.8%−10.7% (better)
Financial health
Debt / equity0.000.00
Current ratio9.3616.35 (better)
Altman Z-score0.865.13 (better)
Piotroski F-score22
Dividends and buybacks
Buyback yield−56.6%–
Shareholder yield−56.6%0.00% (better)
Ownership
Held by institutions97.9%101%
Held by insiders1.5%21.3%
Insider net buying, 12 months−$1.2M−$457K (better)
Short interest, % of float21.1%11.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.